Recursion Pharmaceuticals ... The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 9,589 calls trading, 1.6x expected, and implied vol increasing over 27 ...

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...